- Learn the basics
- Find stocks
- Understand a stock
Pyxis Oncology, Inc.
PYXS United States NASDAQPyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
In short
Loading the key numbers…
What the sector means for this company
These sentences describe the numbers; they are not a recommendation. This content is not investment advice.
Price chart: each candle shows one day's opening, highest, lowest and closing price. The projection line is our model's estimate - a model, not a promise.
Price chart
Key statistics: the most used ratios in one place. Tap the icon next to a name for a short explanation. Compare them with similar companies, not with the whole market.
Financial statements: the income statement shows sales and profit, the balance sheet what the company owns and owes, and the cash flow statement the money that actually came in and went out. How to read them.
Company policy and leadership: an AI-assisted assessment of how the company sells, executes, uses its resources and treats people, production and service. Read it as a starting point for your own research.
News: the latest articles about the company, grouped by day. Each has ratings for the outlet's stance towards the company and how factual it is. What the ratings mean.